Celgene International Sárl Release: Study of REVLIMID® (lenalidomide) in Patients with High-Risk Asymptomatic Smoldering Multiple Myeloma Published in The New England Journal of Medicine
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that data evaluating treatment with REVLIMID® (lenalidomide) in combination with dexamethasone followed by REVLIMID maintenance therapy in patients with high-risk asymptomatic smoldering multiple myeloma were published in the August 1 edition of The New England Journal of Medicine. Smoldering multiple myeloma is an early, asymptomatic form of the disease characterized by a 10% per year risk of progression to symptomatic disease over the first five years.
Help employers find you! Check out all the jobs and post your resume.
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that data evaluating treatment with REVLIMID® (lenalidomide) in combination with dexamethasone followed by REVLIMID maintenance therapy in patients with high-risk asymptomatic smoldering multiple myeloma were published in the August 1 edition of The New England Journal of Medicine. Smoldering multiple myeloma is an early, asymptomatic form of the disease characterized by a 10% per year risk of progression to symptomatic disease over the first five years.
Help employers find you! Check out all the jobs and post your resume.